Skip to main content

Advertisement

SpringerLink
Log in

High expression of SPHK1 in sacral chordoma and association with patients’ poor prognosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Sacral chordoma is an aggressive bone tumor with a high local recurrence rate. Surgery remains the standard treatment because of its resistance to chemotherapy and radiotherapy. However, recurrence occurs frequently even after complete surgical resection. Great effort has been invested in discovering novel biomarkers and therapeutic targets. To date, the molecular mechanism is still unclear. In this study, we evaluated the expression of sphingosine kinase 1 (SPHK1) in 42 sacral chordoma samples and 16 distant normal tissue specimens by immunohistochemical staining. In addition, we analyzed its association with the clinical factors and patients’ prognosis. Of all the chordoma samples, 69 % (29/42) showed high expression of SPHK1, whereas, only 19 % (3/16) of distant normal tissues expressed a high level of SPHK1 (p = 0.001). Chi-square analysis revealed that high expression of SPHK1 was significantly correlated with tumor recurrence (p = 0.019) and invasion into surrounding muscle (p = 0.005), while the data did not indicate any association with patients’ gender, age, tumor location and size (p > 0.05). Kaplan–Meier survival curve and log-rank test showed that patients with high expression of SPHK1 possessed shorter continuous disease-free survival time. Conclusively, SPHK1 may become a potential biomarker for sacral chordoma in predicting its recurrence and patients’ prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control : CCC. 2001;12(1):1–11.

    Article  PubMed  CAS  Google Scholar 

  2. Maclean FM, Soo MY, Ng T. Chordoma: radiological-pathological correlation. Australas Radiol. 2005;49(4):261–8. doi:10.1111/j.1440-1673.2005.01433.x.

    Article  PubMed  CAS  Google Scholar 

  3. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19(4):367–70. doi:10.1097/CCO.0b013e3281214448.

    Article  PubMed  Google Scholar 

  4. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12(11):1344–50. doi:10.1634/theoncologist.12-11-1344.

    Article  PubMed  Google Scholar 

  5. Sciubba DM, Cheng JJ, Petteys RJ, Weber KL, Frassica DA, Gokaslan ZL. Chordoma of the sacrum and vertebral bodies. J Am Acad Orthop Surg. 2009;17(11):708–17.

    PubMed  Google Scholar 

  6. Hanna SA, Aston WJ, Briggs TW, Cannon SR, Saifuddin A. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466(9):2217–23. doi:10.1007/s11999-008-0356-7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Knapp P, Baranowski M, Knapp M, Zabielski P, Blachnio-Zabielska AU, Gorski J. Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins Other Lipid Mediat. 2010;92(1–4):62–6. doi:10.1016/j.prostaglandins.2010.03.002.

    Article  PubMed  CAS  Google Scholar 

  8. Guan H, Liu L, Cai J, Liu J, Ye C, Li M, et al. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol (Baltimore, MD). 2011;25(11):1858-66. doi:10.1210/me.2011-1048.

  9. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer (Oxford, England: 1990). 2010;46(18):3417-24. doi:10.1016/j.ejca.2010.07.053.

  10. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs. 2010;192(5):314–24. doi:10.1159/000318173.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene. 2005;24(1):178–87. doi:10.1038/sj.onc.1208019.

    Article  PubMed  CAS  Google Scholar 

  12. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver. 2012;32(2):331–8. doi:10.1111/j.1478-3231.2011.02666.x.

    Article  CAS  Google Scholar 

  13. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008;9(8):662–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Liu SQ, Su YJ, Qin MB, Mao YB, Huang JA, Tang GD. Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules. Int J Oncol. 2013;42(2):617–26. doi:10.3892/ijo.2012.1733.

    PubMed  CAS  Google Scholar 

  15. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVision ++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51(7):506–11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Yang H, Zhu L, Ebraheim NA, Liu X, Castillo S, Tang T, et al. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Spine J: Off J N Am Spine Soc. 2009;9(12):972–80. doi:10.1016/j.spinee.2009.08.447.

    Article  Google Scholar 

  17. Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, et al. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol (Northwood, London, England). 2014;31(4):886. doi:10.1007/s12032-014-0886-7.

  18. Chen KW, Yang HL, Lu J, Liu JY, Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2010;48(2):166–71. doi:10.1038/sc.2009.95.

    Article  PubMed  CAS  Google Scholar 

  19. Chen KW, Yang HL, Lu J, Wang GL, Ji YM, Wu GZ, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neuro-Oncol. 2011;101(3):357–63. doi:10.1007/s11060-010-0263-0.

    Article  CAS  Google Scholar 

  20. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology. 2009;150(10):4484–92. doi:10.1210/en.2009-0391.

    Article  PubMed  CAS  Google Scholar 

  21. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(4):1393–9. doi:10.1158/1078-0432.ccr-08-1158.

    Article  CAS  Google Scholar 

  22. Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 2011;9:157. doi:10.1186/1479-5876-9-157.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Akhavan-Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H. Expression of PDGFR-alpha, EGFR and c-MET in spinal chordoma: a series of 52 patients. Anticancer Res. 2014;34(2):623–30.

    PubMed  Google Scholar 

  24. Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, et al. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett. 2004;577(3):333–8. doi:10.1016/j.febslet.2004.10.024.

    Article  PubMed  CAS  Google Scholar 

  25. Sinha UK, Schorn VJ, Hochstim C, Chinn SB, Zhu S, Masood R. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. Head Neck. 2011;33(2):178–88. doi:10.1002/hed.21418.

    Article  PubMed  Google Scholar 

  26. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol. 2010;177(5):2205–15. doi:10.2353/ajpath.2010.100220.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012;106(8):1453–9. doi:10.1038/bjc.2012.98.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Song L, Xiong H, Li J, Liao W, Wang L, Wu J, et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3 K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(7):1839–49. doi:10.1158/1078-0432.ccr-10-0720.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Gu Yongping for technical guidance during the immunohistochemical analysis.

Conflict of interest

None.

Ethical standard

Our study was approved by the Committee on Medical Ethics of the First affiliated Hospital of Soochow University.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215006, Jiangsu, China

    Kai Zhang, Hao Chen, Guizhong Wu, Kangwu Chen & Huilin Yang

Authors
  1. Kai Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guizhong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kangwu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huilin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kangwu Chen or Huilin Yang.

Additional information

K. Zhang and H. Chen have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, K., Chen, H., Wu, G. et al. High expression of SPHK1 in sacral chordoma and association with patients’ poor prognosis. Med Oncol 31, 247 (2014). https://doi.org/10.1007/s12032-014-0247-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0247-6

Keywords

Search

Navigation